2136259
Project Grant
Overview
Grant Description
Sbir Phase I: Localized and Sustained Antibiotic Delivery for Treatment of Periprosthetic Joint Infection (PJI) in Arthroplasty Patients - The broader impact of this Small Business Innovation Research (SBIR) Phase I project is develop an innovative medical technology for localized and sustained antibiotic treatment in the case of periprosthetic joint infection (PJI).
The proposed activities may result in commercialization of an implant with novel reservoir technology to be placed at the infected site, and which will locally deliver antibiotics to eradicate the infection. This solution may improve patient care as well as reduce costs associated with treatment of infection.
The development of an implantable, antibiotic-eluting orthopedic spacer which enables patients to return to ambulatory conditions while providing sustained, appropriate, anti-infection resistance for a sustained duration could benefit patients and reduce medical costs. The proposed product seeks to reduce infections and reduce the need for surgical revision and significant antibiotic treatments. If successful, this technology will reduce the burden associated with unresolved infections and avoid amputations.
This team will design, develop, and validate the proof of concept for an orthopedic spacer. The system will be 3-D printed using a novel porous medium capable of controlled antibiotic elution. The product will be tested using benchtop mechanical testing and in vitro studies of implanted system viability and controlled elution.
The objectives include a study of the prototype's ability to meet design criteria for mechanical performance, as well as a demonstration of a superior antibiotic elution profile over an extended-release period. The mechanical testing to be performed include load, stress, and cycle testing within current standards, in conjunction with in vitro laboratory elution testing of the specified antibiotic substance over a sustained duration of time (up to >180 days).
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
The proposed activities may result in commercialization of an implant with novel reservoir technology to be placed at the infected site, and which will locally deliver antibiotics to eradicate the infection. This solution may improve patient care as well as reduce costs associated with treatment of infection.
The development of an implantable, antibiotic-eluting orthopedic spacer which enables patients to return to ambulatory conditions while providing sustained, appropriate, anti-infection resistance for a sustained duration could benefit patients and reduce medical costs. The proposed product seeks to reduce infections and reduce the need for surgical revision and significant antibiotic treatments. If successful, this technology will reduce the burden associated with unresolved infections and avoid amputations.
This team will design, develop, and validate the proof of concept for an orthopedic spacer. The system will be 3-D printed using a novel porous medium capable of controlled antibiotic elution. The product will be tested using benchtop mechanical testing and in vitro studies of implanted system viability and controlled elution.
The objectives include a study of the prototype's ability to meet design criteria for mechanical performance, as well as a demonstration of a superior antibiotic elution profile over an extended-release period. The mechanical testing to be performed include load, stress, and cycle testing within current standards, in conjunction with in vitro laboratory elution testing of the specified antibiotic substance over a sustained duration of time (up to >180 days).
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27701-0001
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Analysis Notes
Amendment Since initial award the total obligations have increased 8% from $255,247 to $275,247.
Reselute was awarded
Project Grant 2136259
worth $275,247
from National Science Foundation in February 2022 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Localized and Sustained Antibiotic Delivery For Treatment of Periprosthetic Joint Infection (PJI) in Arthroplasty Patients
Abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is develop an innovative medical technology for localized and sustained antibiotic treatment in the case of periprosthetic joint infection (PJI). The proposed activities may result in commercialization of an implant with novel reservoir technology to be placed at the infected site, and which will locally deliver antibiotics to eradicate the infection. This solution may improve patient care as well as reduce costs associated with treatment of infection. The development of an implantable, antibiotic-eluting orthopedic spacer which enables patients to return to ambulatory conditions while providing sustained, appropriate, anti-infection resistance for a sustained duration could benefit patients and reduce medical costs. The proposed product seeks to reduce infections and reduce the need for surgical revision and significant antibiotic treatments. If successful, this technology will reduce the burden associated with unresolved infections and avoid amputations.This team will design, develop, and validate the proof of concept for an orthopedic spacer. The system will be 3-D printed using a novel porous medium capable of controlled antibiotic elution.The product will be tested using benchtop mechanical testing and in vitro studies of implanted system viability and controlled elution. The objectives include a study of the prototype's ability to meet design criteria for mechanical performance, as well as a demonstration of a superior antibiotic elution profile over an extended-release period. The mechanical testing to be performed include load, stress, and cycle testing within current standards, in conjunction with in vitro laboratory elution testing of the specified antibiotic substance over a sustained duration of time (up togreater than 180 days).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 21-562
Status
(Complete)
Last Modified 7/6/22
Period of Performance
2/15/22
Start Date
1/31/23
End Date
Funding Split
$275.2K
Federal Obligation
$0.0
Non-Federal Obligation
$275.2K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2136259
Additional Detail
Award ID FAIN
2136259
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
JBMRHJGSMFD6
Awardee CAGE
91CW5
Performance District
04
Senators
Thom Tillis
Ted Budd
Ted Budd
Representative
Valerie Foushee
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $275,247 | 100% |
Modified: 7/6/22